Identification and validation of FGFR2 peptide for detection of early Barrett's neoplasia.

ABSTRACT: The incidence of esophageal adenocarcinoma (EAC) is rising rapidly, and early detection within the precursor state of Barrett's esophagus (BE) is challenged by flat premalignant lesions that are difficult detect with conventional endoscopic surveillance. Overexpression of cell surface fibroblast growth factor receptor 2 (FGFR2) is an early event in progression of BE to EAC, and is a promising imaging target. We used phage display to identify the peptide SRRPASFRTARE that binds specifically to the extracellular domain of FGFR2. We labeled this peptide with a near-infrared fluorophore Cy5.5, and validated the specific binding to FGFR2 overexpressed in cells in vitro. We found high affinity k_d = 68 nM and rapid binding k = 0.16 min^-1 (6.2 min). In human esophageal

SUBMITTER: Zhou J 

PROVIDER: S-EPMC5675618 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature